4D Molecular Therapeutics Inc. (FDMT)
FDMT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$12.36
-4.92% on the day
Market cap
$682.8M
Small cap
Revenue · 2025
$85.2M
+230194.6% on 2024
Net income · 2025
-$140.1M
-164.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | FDMT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001650648 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $85.2M |
| Net income | -$140.1M |
| Operating income | -$159.5M |
| Net margin | -164.4% |
| Operating margin | -187.2% |
| Revenue growth | +230194.6% |
| Cash | $60.2M |
| Total assets | $566.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-05-07 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 438 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.3% |
| 1 month | -10.7% |
| 3 months | +12.3% |
| Year to date | +62.3% |
| 1 year | +25.9% |
| From 52-week high | -27.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ATTO | Attovia Therapeutics Inc. | $14.72 | +0.89% | $672.0M |
| CADL | Candel Therapeutics Inc. | $9.27 | -5.21% | $709.3M |
| AURA | Aura Biosciences Inc. | $6.27 | -4.13% | $650.2M |
| SANA | Sana Biotechnology Inc. | $2.41 | -8.02% | $721.5M |
| SLDB | Solid Biosciences Inc. | $5.82 | -13.26% | $624.1M |
| DNA | Ginkgo Bioworks Holdings Inc. | $11.76 | -0.25% | $756.6M |
| PRME | Prime Medicine Inc. | $3.32 | -8.03% | $602.2M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier